8-K: Aldeyra Therapeutics Receives Complete Response Letter from FDA for Dry Eye Disease Treatment Reproxalap

Aldeyra Therapeutics received a Complete Response Letter from the FDA regarding its resubmitted New Drug Application for reproxalap for dry eye disease, citing the need for additional efficacy data.

Summary

• Aldeyra Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its resubmitted New Drug Application (NDA) for reproxalap, a treatment for dry eye disease.
• The FDA stated that the NDA failed to demonstrate efficacy in adequate and well-controlled studies for treating ocular symptoms associated with dry eyes.
• The FDA requires at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye.
• Concerns were raised about the data from the trial submitted to the NDA, potentially related to methodological issues, including differences in baseline scores across treatment arms.
• Aldeyra expects to announce results from two additional dry eye disease trials in the second quarter of 2025.
• Pending positive results and discussions with the FDA, Aldeyra intends to resubmit the NDA mid-year 2025.
• The company had $101 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
• The full-year 2025 costs for the ongoing dry eye clinical trials are expected to be approximately $6 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the FDA's rejection of the NDA, but there's optimism based on ongoing trials and potential resubmission. The company's financial position is stable, which provides some reassurance.

Positives

• No manufacturing or safety issues with reproxalap were identified by the FDA.
• Aldeyra has $101 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing financial flexibility.
• Top-line results from dry eye disease field and chamber clinical trials are expected in Q2 2025.
• Aldeyra expects to hold a Type A meeting with the FDA within approximately 30 days to discuss the CRL and ongoing clinical trials.

Negatives

• The FDA issued a Complete Response Letter for the resubmitted NDA for reproxalap.
• The FDA stated that the NDA failed to demonstrate efficacy in adequate and well-controlled studies.
• At least one additional adequate and well-controlled study is required to demonstrate a positive effect on the treatment of ocular symptoms of dry eye.
• The FDA identified concerns with the data from the trial submitted to the NDA, potentially related to methodological issues.

Risks

• Aldeyra's success depends on addressing the issues raised by the FDA in the Complete Response Letter.
• The FDA could require additional studies or clinical trials, delaying acceptance and/or approval of a potential NDA resubmission.
• Regulatory approval of reproxalap may be limited to certain patient populations or include extensive warnings on the product labeling.
• Any regulatory approval of reproxalap, once obtained, may be withdrawn.
• Failure to obtain and maintain regulatory approvals would prevent reproxalap from being marketed and would have a material adverse effect on Aldeyra's business.

Future Outlook

Aldeyra expects to announce results from two additional dry eye disease trials in the second quarter of 2025 and intends to resubmit the NDA mid-year 2025, pending positive results and discussions with the FDA; the review period for the potential NDA resubmission is expected to be six months.

Management Comments

• Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra Therapeutics, stated, 'Pending positive results from the ongoing clinical trials and discussions with the FDA, we look forward to a potential NDA resubmission mid-year 2025.'
• He also noted that 'Reproxalap remains the only late-stage topical ocular therapy suitable for chronic administration to have potentially demonstrated acute reduction in ocular redness, as well as reduction in ocular discomfort, highlighting rapid and broad activity for both the signs and symptoms of dry eye disease.'

Industry Context

The dry eye disease market is a significant area of unmet need, with 39 million or more adults in the United States affected; reproxalap aims to offer a novel therapeutic approach with rapid activity in clinical trials, potentially shifting the treatment paradigm.

Comparison to Industry Standards

• The document mentions that, per draft FDA dry eye disease guidance, efficacy may be demonstrated with two symptom trials and two sign trials, which is a standard benchmark for regulatory approval in the United States.
• Reproxalap's potential to demonstrate acute reduction in ocular redness and discomfort is compared to the standard of care, suggesting a potential advantage over existing treatments.

Stakeholder Impact

• Shareholders may experience a negative impact due to the delay in potential approval of reproxalap.
• Patients with dry eye disease may face a delay in accessing a new treatment option.
• Employees of Aldeyra may experience uncertainty related to the future of the reproxalap program.

Next Steps

• Aldeyra expects to hold a Type A meeting with the FDA within approximately 30 days.
• Top-line results from dry eye disease field and chamber clinical trials are expected in Q2 2025.
• Aldeyra intends to resubmit the NDA mid-year 2025, pending positive results and discussions with the FDA.

Key Dates

Keywords

reproxalap, dry eye disease, FDA, Complete Response Letter, NDA, clinical trials, regulatory approval, Aldeyra Therapeutics, efficacy, ocular symptoms